Evidence map›Paper›PMID 39780302›Full record

ArticleCell transplantation

Impact of Tacrolimus, Sirolimus, Age, and Body Mass Index on the Occurrence of Skin Cancer and Islet Dysfunction After Transplantation.

Christopher Orr, Jeannette Stratton, Mohamed El-Shahawy, Elena Forouhar, Alice Peng, Gagandeep Singh, Keiko Omori, Meirigeng Qi, Fouad Kandeel

Abstract read
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. De Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher OrrDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.ORCID 0000-0001-9123-5101
Jeannette StrattonDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Mohamed El-ShahawyDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Elena ForouharDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Alice PengKidney & Pancreas Transplant Program, Cedars-Sinai Medical Center, Los Angeles, CA. USA.
Gagandeep SinghDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Keiko OmoriDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Meirigeng QiDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Fouad KandeelDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.

Funding

SOUTHERN CALIFORNIA ISLET CELL RESOURCES (SCI-ICR) CENTERU42RR016607 · NCRR · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI RIGGS, ARTHUR D · 2001 to 2009
$6.6M
NCRR NIH HHS U42 RR016607
6 · The paper itself

Abstract

Herein, we characterized the percentage of tacrolimus to the combined sirolimus and tacrolimus trough levels (tacrolimus %) observed during islet transplant-associated immune suppression therapy with post-transplant skin cancer. Although trough levels of tacrolimus and sirolimus were not different (

Indexed as

Body Mass IndexImmunosuppressive AgentsSirolimusSkin NeoplasmsTacrolimusAdultAgedAge FactorsFemaleHumansIslets of Langerhans TransplantationMaleMiddle AgedImmunosuppressive AgentsSirolimusTacrolimusbasal cell carcinomaislet cell transplantationislet graft dysfunctionmelanomasirolimussquamous cell carcinomatacrolimus

Identifiers

PMID39780302
PMCPMC11713960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.